Varma Mutual Pension Insurance Co Raises Stock Position in DexCom, Inc. $DXCM

Varma Mutual Pension Insurance Co boosted its holdings in DexCom, Inc. (NASDAQ:DXCM) by 100.0% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 20,000 shares of the medical device company’s stock after buying an additional 10,000 shares during the period. Varma Mutual Pension Insurance Co’s holdings in DexCom were worth $1,327,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of DXCM. Brighton Jones LLC increased its stake in DexCom by 257.7% in the 4th quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company’s stock worth $1,290,000 after buying an additional 11,946 shares in the last quarter. Integrated Wealth Concepts LLC increased its stake in DexCom by 6.3% in the 1st quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock worth $227,000 after buying an additional 196 shares in the last quarter. Empowered Funds LLC increased its stake in DexCom by 5.4% in the 1st quarter. Empowered Funds LLC now owns 8,446 shares of the medical device company’s stock worth $577,000 after buying an additional 436 shares in the last quarter. Focus Partners Wealth grew its holdings in DexCom by 13.2% during the 1st quarter. Focus Partners Wealth now owns 7,218 shares of the medical device company’s stock valued at $493,000 after buying an additional 841 shares in the last quarter. Finally, NewEdge Advisors LLC grew its holdings in DexCom by 1.4% during the 2nd quarter. NewEdge Advisors LLC now owns 19,253 shares of the medical device company’s stock valued at $1,681,000 after buying an additional 258 shares in the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Insider Buying and Selling

In other DexCom news, EVP Michael Jon Brown sold 1,700 shares of DexCom stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $63.04, for a total transaction of $107,168.00. Following the completion of the transaction, the executive vice president directly owned 111,204 shares of the company’s stock, valued at $7,010,300.16. The trade was a 1.51% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.28% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on DXCM. Mizuho set a $75.00 price objective on shares of DexCom in a report on Friday. Piper Sandler reaffirmed an “overweight” rating on shares of DexCom in a report on Thursday, February 5th. Canaccord Genuity Group set a $100.00 price objective on shares of DexCom and gave the company a “buy” rating in a report on Friday. TD Cowen cut their price objective on shares of DexCom from $84.00 to $75.00 and set a “buy” rating for the company in a report on Friday, May 1st. Finally, Raymond James Financial set a $81.00 price objective on shares of DexCom in a report on Friday. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $83.50.

DexCom Stock Down 0.9%

NASDAQ DXCM opened at $59.48 on Wednesday. The company has a quick ratio of 1.64, a current ratio of 1.95 and a debt-to-equity ratio of 0.42. The company has a fifty day moving average of $65.60 and a two-hundred day moving average of $66.37. The firm has a market capitalization of $22.95 billion, a price-to-earnings ratio of 25.42, a PEG ratio of 1.04 and a beta of 1.40. DexCom, Inc. has a 52 week low of $54.11 and a 52 week high of $89.98.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, April 30th. The medical device company reported $0.56 EPS for the quarter, topping the consensus estimate of $0.47 by $0.09. The company had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.17 billion. DexCom had a net margin of 19.31% and a return on equity of 33.33%. DexCom’s quarterly revenue was up 15.0% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.32 earnings per share. On average, analysts predict that DexCom, Inc. will post 2.55 earnings per share for the current year.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.